People with a rare genetic form of high cholesterol caused by two broken copies of the LDLR gene don’t get much benefit from PCSK9 inhibitor drugs — most see almost no drop in their bad cholesterol.

People with a rare genetic cholesterol disorder who still have a little bit of working cholesterol-cleaning system in their body tend to respond better to a certain type of cholesterol drug, lowering their bad cholesterol by about 20% on average.

For people with a rare cholesterol condition called HoFH who are already on cholesterol meds, adding a newer drug (PCSK9 inhibitor) barely lowers bad cholesterol for most — and 7 out of 10 don’t get enough benefit to keep taking it.

People in Saudi Arabia with a rare cholesterol condition don’t seem to lower their bad cholesterol as much with a certain drug as other people did in past studies — and it might be because of their genes or how the treatment is used in real clinics.

People with a rare cholesterol condition stayed on a pricey cholesterol drug for about a year on average, even though it didn’t help much — doctors might just keep prescribing it because they’re hesitant to stop treatments that aren’t working.

Even when people with a rare genetic cholesterol disorder take powerful new drugs called PCSK9 inhibitors along with their usual treatments, none of them got their bad cholesterol down to the recommended healthy levels.